FdaApplication
NDA 213702
Identifiers
- fda_app_no: NDA213702
Properties
| Property | Value |
|---|---|
| applicant_name | JAZZ PHARMACEUTICALS IRELAND LTD |
| application_type | NDA |
| approval_date | 2020-06-15 |
Revenue by product
ZEPZELCA
| Period | Revenue |
|---|---|
| Q2 2026 | $105.8M |
| Q1 2026 | $101.0M |
| Q4 2025 | $90.4M |
| Q3 2025 | $79.3M |
| Q2 2025 | $74.5M |
| Q1 2025 | $63.0M |
| Q4 2024 | $78.3M |
| Q3 2024 | $85.8M |
| Q2 2024 | $81.0M |
| Q1 2024 | $75.1M |
| Q4 2023 | $74.0M |
| Q3 2023 | $78.0M |
| Q2 2023 | $70.3M |
| Q1 2023 | $67.2M |
| Q4 2022 | $72.0M |
| Q3 2022 | $70.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZEPZELCA | LURBINECTEDIN | 4MG/VIAL | POWDER;INTRAVENOUS |
1 product